Advertisement
ANVS vs JAZZ
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANVS is a Hold and JAZZ is a Hold.
ANVS in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 05, 2026
ANVS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 35 cases where ANVS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ANVS's RSI Indicator exited the oversold zone, 26 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 69 cases where ANVS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
Following a +34.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANVS advanced for three days, in 193 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ANVS as a result. In 73 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for ANVS turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 43 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ANVS entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-8.475) is normal, around the industry mean (3.498). P/E Ratio (-0.483) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. ANVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
JAZZ in upward trend: price rose above 50-day moving average on November 06, 2026
JAZZ moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend. In 33 of 50 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 66%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on JAZZ as a result. In 57 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 58%.
The Moving Average Convergence Divergence (MACD) for JAZZ just turned positive on October 29, 2026. Looking at past instances where JAZZ's MACD turned positive, the stock continued to rise in 31 of 49 cases over the following month. The odds of a continued upward trend are 63%.
Following a +4.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where JAZZ advanced for three days, in 176 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JAZZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
JAZZ broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JAZZ entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 28 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. JAZZ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.174) is normal, around the industry mean (3.498). P/E Ratio (15.435) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.941) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.407) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
ANVS | JAZZ | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 5 | 23 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 13 Undervalued | 86 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 28 | |
SMR RATING 1..100 | 100 | 44 | |
PRICE GROWTH RATING 1..100 | 89 | 40 | |
P/E GROWTH RATING 1..100 | 10 | 97 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ANVS's Valuation (13) in the null industry is significantly better than the same rating for JAZZ (86) in the Pharmaceuticals Other industry. This means that ANVS’s stock grew significantly faster than JAZZ’s over the last 12 months.
JAZZ's Profit vs Risk Rating (28) in the Pharmaceuticals Other industry is significantly better than the same rating for ANVS (100) in the null industry. This means that JAZZ’s stock grew significantly faster than ANVS’s over the last 12 months.
JAZZ's SMR Rating (44) in the Pharmaceuticals Other industry is somewhat better than the same rating for ANVS (100) in the null industry. This means that JAZZ’s stock grew somewhat faster than ANVS’s over the last 12 months.
JAZZ's Price Growth Rating (40) in the Pharmaceuticals Other industry is somewhat better than the same rating for ANVS (89) in the null industry. This means that JAZZ’s stock grew somewhat faster than ANVS’s over the last 12 months.
ANVS's P/E Growth Rating (10) in the null industry is significantly better than the same rating for JAZZ (97) in the Pharmaceuticals Other industry. This means that ANVS’s stock grew significantly faster than JAZZ’s over the last 12 months.
| ANVS | JAZZ | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 79% | 2 days ago 52% |
| Stochastic ODDS (%) | 2 days ago 75% | 2 days ago 61% |
| Momentum ODDS (%) | 2 days ago 87% | 2 days ago 58% |
| MACD ODDS (%) | 2 days ago 88% | 2 days ago 63% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 62% |
| TrendMonth ODDS (%) | 2 days ago 89% | 2 days ago 67% |
| Advances ODDS (%) | 3 days ago 80% | 2 days ago 59% |
| Declines ODDS (%) | 24 days ago 90% | 17 days ago 55% |
| BollingerBands ODDS (%) | 2 days ago 86% | 2 days ago 64% |
| Aroon ODDS (%) | 2 days ago 89% | 2 days ago 60% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ANVS’s FA Score shows that 2 FA rating(s) are green while JAZZ’s FA Score has 1 green FA rating(s).
- ANVS’s FA Score: 2 green, 3 red.
- JAZZ’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ANVS’s TA Score shows that 4 TA indicator(s) are bullish while JAZZ’s TA Score has 4 bullish TA indicator(s).
- ANVS’s TA Score: 4 bullish, 4 bearish.
- JAZZ’s TA Score: 4 bullish, 5 bearish.
Price Growth
ANVS (@Biotechnology) experienced а -19.79% price change this week, while JAZZ (@Biotechnology) price change was +6.83% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
ANVS is expected to report earnings on Nov 11, 2026.
JAZZ is expected to report earnings on Mar 02, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ANVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, ANVS has been loosely correlated with DMAC. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ANVS jumps, then DMAC could also see price increases.
| Ticker / NAME | Correlation To ANVS | 1D Price Change % | ||
|---|---|---|---|---|
| ANVS | 100% | -3.00% | ||
| DMAC - ANVS | 48% Loosely correlated | +0.21% | ||
| ADXN - ANVS | 43% Loosely correlated | +8.03% | ||
| JAZZ - ANVS | 39% Loosely correlated | +0.77% | ||
| MDGL - ANVS | 36% Loosely correlated | -0.04% | ||
| ABEO - ANVS | 36% Loosely correlated | -3.35% | ||
More | ||||
JAZZ and
Correlation & Price change
A.I.dvisor indicates that over the last year, JAZZ has been loosely correlated with ZYME. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if JAZZ jumps, then ZYME could also see price increases.
| Ticker / NAME | Correlation To JAZZ | 1D Price Change % | ||
|---|---|---|---|---|
| JAZZ | 100% | +0.77% | ||
| ZYME - JAZZ | 52% Loosely correlated | +2.11% | ||
| AMLX - JAZZ | 43% Loosely correlated | +2.32% | ||
| DYN - JAZZ | 43% Loosely correlated | -3.76% | ||
| CLDX - JAZZ | 42% Loosely correlated | -1.89% | ||
| JBIO - JAZZ | 41% Loosely correlated | +5.13% | ||
More | ||||